STOCK TITAN

COVALON TECHS LTD - CVALF STOCK NEWS

Welcome to our dedicated page for COVALON TECHS news (Ticker: CVALF), a resource for investors and traders seeking the latest updates and insights on COVALON TECHS stock.

Covalon Technologies Ltd. is a global leader in researching, developing, and commercializing healthcare technologies that save lives worldwide. With patented products and services, Covalon addresses medical device companies, healthcare providers, and individual consumers' advanced healthcare needs. Specializing in wound care, tissue repair, infection control, disease management, medical device coatings, and biocompatibility, Covalon's technologies prevent, detect, and manage various medical conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Covalon Technologies Ltd. (TSXV: COV, OTCQX: CVALF) has announced its participation in the 48th Annual Canadian Vascular Access Association (CVAA) Conference and World Congress on Vascular Access, taking place from April 26 to April 28, 2023, in Toronto, Canada. The conference will focus on advancements in infusion therapy and vascular access practices. Covalon aims to showcase its vascular access infection prevention solutions, including CovaClear IV, IV Clear, and VALGuard, designed to improve patient care and comfort. Senior VP Ron Hebert expressed enthusiasm about the opportunity to share insights on their innovative products that cater to both patients and healthcare providers. Attendees can visit Covalon’s booth for more information or connect via email for appointments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
none
Rhea-AI Summary

Covalon Technologies Ltd. (TSXV:COV)(OTCQX:CVALF) will present at the Planet MicroCap Showcase: VEGAS 2023 on April 26, 2023, at 8:30 AM PDT. President and CEO Brian Pedlar will lead the presentation and answer questions afterward. Live access to the presentation can be found here.

Covalon specializes in advanced medical technologies, offering patented products that aim to protect patients from infections and facilitate healing. Their FDA-approved solutions are particularly beneficial for individuals dealing with chronic wounds or surgical recovery.

For those unable to attend the live session, all presentations will be available for viewing on the conference platform. Additionally, registered participants can schedule one-on-one meetings with Covalon representatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Covalon Technologies Ltd. (CVALF) is hosting a webinar titled "Protecting CVADs from Gross Contamination" on March 29, 2023, to combat the rising incidents of central line-associated bloodstream infections (CLABSIs), which have surged by 47% since the COVID-19 pandemic according to the CDC. The session, led by expert Matthew Ostroff, will discuss innovative solutions to prevent CLABSIs, particularly in pediatric healthcare settings. This webinar is part of Covalon's CLABSI Conscious campaign aimed at improving patient safety and reducing infection rates through advanced medical technology and expert guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
none
-
Rhea-AI Summary

Covalon Technologies Ltd., trading under the symbol CVALF, recently announced its participation in the Synova NICU Leadership Forum from March 19 to March 23, 2023, in Tucson, Arizona. The company will showcase its innovative infection prevention solutions at booth 106, emphasizing compassion in patient care, particularly for NICU and pediatric patients. Covalon's products, like the CovaClear IV and VALGuard, aim to improve patient outcomes while reducing stress for healthcare providers. Six of the top ten children's hospitals have adopted these solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Covalon Technologies Ltd. announced the results of its Fiscal 2022 Annual and Special Meeting of Shareholders held on March 8, 2023. Shareholders approved all matters including the election of the Board of Directors, the appointment of auditors, and the Omnibus Long-Term Incentive Plan. A total of 12,803,487 shares, or 51.076%, were represented at the meeting. Notable voting results included Amir Boloor receiving 92.275% support and PricewaterhouseCoopers receiving 99.996% approval as auditors. The detailed voting results will be filed on SEDAR with further information available in the management information circular dated February 1, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Covalon Technologies Ltd. announced on March 9, 2023, the appointment of Martin Goldfarb to its Board of Directors. Goldfarb, a long-standing shareholder, has over a decade of involvement with Covalon and brings substantial experience in brand and strategic development. CEO Brian Pedlar expressed enthusiasm for Goldfarb's insights, highlighting his extensive entrepreneurial background. Goldfarb's previous roles include Chairman of Almada Inc. and President of Goldfarb Ventures. His appointment is subject to TSX approval. Covalon is focused on innovating healthcare by developing advanced medical technologies aimed at improving patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

Covalon Technologies Ltd. (CVALF) announced its annual and special shareholder meeting scheduled for March 8, 2023, at 3:30 PM EST, to be held virtually. Registered shareholders and proxyholders can attend through a live webcast. Non-registered shareholders must appoint themselves as proxyholders to vote online. The meeting will cover important company matters and allow shareholder participation.

Details for accessing the meeting can be found on the company’s official website. Additional resources like the Management Information Circular and financial statements are available on SEDAR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Covalon Technologies reported a strong fiscal Q1 2023 with a 25% revenue growth, totaling $6.2 million, compared to $4.9 million in Q1 2022. The company achieved a 60% gross margin, significantly up from 46% year-over-year, attributed to improved supply chain and operational efficiencies. Net loss narrowed to $0.4 million or $0.02 per share, compared to $1.5 million or $0.06 per share last year. Covalon continues to strengthen its market presence, particularly in the U.S., and has a solid cash position of $14.1 million with no debt, fueling future growth initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags

FAQ

What is the current stock price of COVALON TECHS (CVALF)?

The current stock price of COVALON TECHS (CVALF) is $2.65 as of November 22, 2024.

What is the market cap of COVALON TECHS (CVALF)?

The market cap of COVALON TECHS (CVALF) is approximately 78.9M.

What does Covalon Technologies Ltd. specialize in?

Covalon specializes in researching, developing, and commercializing healthcare technologies for wound care, tissue repair, infection control, disease management, medical device coatings, and biocompatibility.

Which sectors does Covalon cater to?

Covalon caters to medical device companies, healthcare providers, and individual consumers globally.

What is unique about Covalon's patented technologies?

Covalon's patented technologies are designed to prevent, detect, and manage various medical conditions, setting them apart as a global leader in healthcare technology.

Where can I find more information about Covalon Technologies Ltd.?

For more information about Covalon Technologies Ltd., visit their official website at www.covalon.com.

How does Covalon Technologies Ltd. contribute to the healthcare industry?

Covalon contributes to the healthcare industry by offering innovative solutions that address advanced healthcare needs and help save lives around the world.

What is the mission of Covalon Technologies Ltd.?

Covalon's mission is to research, develop, and commercialize healthcare technologies that make a significant impact in preventing, detecting, and managing medical conditions.

Why is Covalon Technologies Ltd. considered a global leader in healthcare technologies?

Covalon is considered a global leader due to its focus on innovation, patented technologies, and commitment to addressing critical healthcare needs worldwide.

How does Covalon Technologies Ltd. contribute to wound care and infection control?

Covalon specializes in technologies that are crucial for wound care, infection control, and other specialty areas to improve patient outcomes and healthcare standards.

What sets Covalon Technologies Ltd. apart from other healthcare technology companies?

Covalon's focus on advanced medical solutions, patented technologies, and global reach distinguish it from other healthcare technology companies in the industry.

What are the core values of Covalon Technologies Ltd.?

Covalon values innovation, quality, patient care, and global impact in its mission to provide cutting-edge healthcare technologies to improve lives worldwide.

COVALON TECHS LTD

OTC:CVALF

CVALF Rankings

CVALF Stock Data

78.91M
11.71M
48.7%
Biotechnology
Healthcare
Link
United States of America
Mississauga